Core Viewpoint - The public science day event organized by the Chinese Academy of Sciences successfully engaged over 5,000 attendees, showcasing the intersection of science and entertainment through interactive experiments and demonstrations [1][2][3][4] Group 1: Event Highlights - The event featured a variety of interactive science experiments, including a performance titled "Nezha is Here! Unlocking the Superpowers in Movies," which explained the scientific principles behind mythical abilities [1] - Attendees experienced hands-on demonstrations, such as water-repellent paper made from modified cellulose, showcasing innovative materials inspired by nature [1][2] - The "Liquid Nitrogen Ice Cream" booth attracted significant attention, illustrating the fun side of science through culinary applications [2] Group 2: Scientific Engagement - The event included over 30 interactive experiments covering diverse scientific fields such as photochemistry, bionic materials, low-temperature physics, and crystal lasers, making complex scientific concepts accessible to the public [2] - A "Low-Temperature Cryotherapy Experience Chamber" allowed participants to experience extreme cold safely, highlighting the practical applications of scientific research in sports recovery [3] - The event fostered dialogue between researchers and the public, transforming complex scientific work into engaging and relatable experiences [3][4] Group 3: Impact on Public Perception - The event inspired young attendees, with children expressing aspirations to invent advanced materials, indicating a successful cultivation of scientific curiosity and ambition [4] - The interactive nature of the event helped demystify scientific research, making it more approachable and enjoyable for the general public [3][4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [8] Core Views - The company reported a revenue of 1.625 billion yuan in 2024, representing a year-on-year growth of 57.21%, and a net profit attributable to shareholders of 404.39 million yuan, which is an increase of 148.19% [8] - The revenue from the self-selected product segment grew significantly, with the peptide API segment achieving a revenue of 948 million yuan, up 127.72% [8] - The custom products segment maintained a high growth rate, with revenue reaching 494 million yuan, an increase of 22.34% [8] - The company is expected to benefit from the high demand in the peptide API industry, with projected net profits of 5.59 billion yuan in 2025 and 7.11 billion yuan in 2026 [8] Financial Summary - Total revenue forecast for 2023A is 1.034 billion yuan, increasing to 4.278 billion yuan by 2027E, with a compound annual growth rate (CAGR) of 37.74% [8] - The net profit attributable to shareholders is expected to grow from 162.94 million yuan in 2023A to 872.54 million yuan in 2027E, reflecting a CAGR of 22.74% [8] - The latest diluted EPS is projected to rise from 0.74 yuan in 2023A to 3.97 yuan in 2027E [8] - The current P/E ratio is 29.46 for 2024A, decreasing to 13.65 by 2027E [8]